Instructions for the targeted drug Capmatinib

1. Indications: Capmatinib (Capmatinib) is a tyrosine kinase inhibitor mainly used to treat specific types of cancer. Specific indications are: patients with advanced or metastatic non-small cell lung cancer (NSCLC) with primary tyrosine kinase overexpression (METex14 skipping mutation or MET increase).

2. Mechanism of action: Capmatinib inhibits the growth, proliferation and spread of tumor cells by specifically inhibiting the activity of MET (liver growth factor receptor) tyrosine kinase and blocking its signal transduction pathway.

3. Pharmacology: Capmatinib is rapidly absorbed in the body and metabolized byCYP3Aenzyme to produce active metabolites. The drug is mainly metabolized by the liver and excreted as major metabolites, with a small amount excreted by the kidneys. Drug metabolism is linear across the dose range administered. Dosage adjustments are recommended based on the patient's liver function.

4. Dosage and usage: Usually, the recommended dose of capmatinib is400mg administered orally twice a day. It is recommended to take it after meals and avoid taking it with drugs containing proton pump inhibitors to reduce drug-drug interactions.

5. Side effects: The use of capmatinib may cause some side effects, including but not limited to:

1.Nausea, vomiting, diarrhea;

2.Skin rash, itching, dry skin;

3.Fatigue, weakness;

4.Loss of appetite;

5.Skeletal muscle pain;

6.Hematological abnormalities (such as anemia, thrombocytopenia);

7.Abnormal liver function.

6. Warnings and precautions:

1.Patients' liver function and complete blood counts should be closely monitored while using capmatinib, especially during the early stages of treatment.

2.If severe skin reactions, liver function damage or other serious adverse reactions occur, you should stop using the drug immediately and seek medical help.

3.Pregnant women are prohibited from using this drug because it may cause damage to the fetus.

4.During the use of capmatinib, avoid concurrent use or discontinue proton pump inhibitors to reduce drug-drug interactions.

5.Capmatinib may cause eye problems, so your vision and eye condition should be checked regularly.

7. Contraindications: Capmatinib is contraindicated in patients who are allergic to the drug. In addition, pregnant and breastfeeding women are also prohibited from using the drug.

8. Drug interactions:

1.Capmatinib is a substrate of CYP3Aenzyme, so simultaneous use of CYP3A4 inducers (such as ribavirin, carbamazepine, etc.) or inhibitors (such as clonazepam, fluconazole, etc.) may affect the metabolism of the drug, thus affecting the efficacy and safety.

2.Concomitant use of proton pump inhibitors may reduce the bioavailability of capmatinib.

3.When using capmatinib, avoid concurrent use with other drugs that may cause liver damage.

9. Medication for special groups:

Geriatric: Elderly patients should use capmatinib with caution and dose adjustments may be necessary.

1.Children: There are currently insufficient research data on use in children, so use of this drug in children under18 years is not recommended.

2.Pregnant and lactating women: Pregnant and lactating women are prohibited from using this drug because it may cause adverse effects on the fetus or infant.

10. Availability and price situation: Capmatinib is not currently available in the country, so patients cannot purchase it domestically. Capmatinib abroad is divided into original drugs and generic drugs. The original drug is mainly the original drug of Novartis, with a price of about 35,000 yuan and a specification of 200mg*60; the price of generic drugs is very cheap, mainly Laos generic drugs, with a price of about 3,000 to 4,000 yuan. The ingredients of original drugs and generic drugs are basically the same.

The above is a detailed description of capmatinib, including indications, mechanism of action, pharmacology, dosage and usage, side effects, warnings and precautions, contraindications, drug interactions, and medication for special groups. But please note again that this is for reference only. Please be sure to check the latest medical information and official instructions before using the drug, and follow your doctor's advice.